Skip to main content

Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP)

The National Cancer Institute (NCI) invites National Clinical Trials Network (NCTN) Groups and NCI Community Oncology Research Program (NCORP) Research Bases to apply for funding to support biomarker, imaging, and symptom science/quality of life (symptom science/QOL) studies. All study applications must be associated with NCI clinical trial concepts or protocols.

Applications must be associated with the following types of trials conducted by NCTN Groups or NCORP Research Bases and reviewed by the NCI Steering Committees:

  • Randomized phase 2 or phase 3 treatment trials
  • Randomized phase 2 or phase 3 prevention trials
  • Randomized symptom science/supportive care clinical trials
  • Non-randomized phase 2 or phase 3 treatment trials (integral studies only)

ANNOUNCEMENT: FY20 BIQSFP Supplements to Support NRT Integrated Studies to Validate Biomarkers, Imaging Tests, or QOL/PRO Instruments

This one-time funding opportunity is for Biomarker, Imaging, and Quality of Life Studies Funding Program (BIQSFP) supplements to support non-real time (NRT) integrated studies that are associated with NCI clinical trials conducted by National Clinical Trials Network (NCTN) groups and NCI Community Oncology Research Program (NCORP) Research Bases.

Letter of Intent Deadline: June 1, 2020

Application Deadline: June 26, 2020

For information on Award and Eligibility Requirements, and Application Information and Instructions, please click here


The following resources are available to assist you with your Application Package:

  • Updated: